A roundup of scientific studies on the novel coronavirus and efforts to find treatments and vaccines includes research on Covid-19 patients who still have symptoms 6 months after falling ill.
Evidence continues to build for long-lasting immunity to Covid-19 following disease infection, with the publication of a new study showing a durable immune response as far as eight months after the initial onset of symptoms.
Apex Innovative Sciences and the company’s affiliates announced their participation in three Covid-19 vaccine studies.
Regeneron Pharmaceuticals Inc. said initial data from an ongoing study of the company’s experimental antibody cocktail for use in hospitalized Covid-19 patients requiring low-flow oxygen show the therapy was sufficiently effective to warrant continuing the trial.
Incyte and Novartis announced a Phase III study of Jakafi (ruxolitinib), a first-in-class JAK1/JAK2 inhibitor, failed to hit endpoints as a treatment for patients 12 and up with Covid-19 associated cytokine storm.
A single-patient study conducted by British scientists found that Gilead’s remdesivir could be highly effective against Covid-19, raising questions about previous studies that found the antiviral drug had no impact on death rates from the disease.
Five key genes are linked with the most severe form of Covid-19, scientists said, in research that also pointed to several existing drugs that could be repurposed to treat people who risk getting critically ill with the pandemic disease.
A study showed the use of convalescent plasma provided no clinical benefit nor improved mortality in Covid-19 patients with pneumonia.
The Covid-19-causing coronavirus is mutating while spreading around the world in the pandemic, but none of the mutations currently documented appears to be making the SARS-CoV-2 virus able to spread more rapidly, scientists said.
Using blood plasma from Covid-19 survivors to treat patients with severe pneumonia caused by the novel coronavirus showed little benefit, according to data released from a clinical trial in Argentina.